UPC
NASDAQUniverse Pharmaceuticals Inc.
Price$2.89-1.60 (-35.63%)
2026-01-212026-04-24
News · 26 weeks11-83%
2025-10-262026-04-19
Mix1090d
- Insider6(60%)
- Other2(20%)
- SEC Filings2(20%)
Latest news
25 items- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- INSIDERSEC Form 3 filed by Universe Pharmaceuticals Inc.3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by Universe Pharmaceuticals Inc.3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by Universe Pharmaceuticals Inc.3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by new insider Yang Lin (Lydia)3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lai Gang3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- INSIDERSEC Form 3 filed by Universe Pharmaceuticals Inc.3 - Universe Pharmaceuticals INC (0001809616) (Issuer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- PRUniverse Pharmaceuticals INC Announces Effective Date of Dual-Class Share StructureJi'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026. In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company's authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of pa
- SECSEC Form 20-F filed by Universe Pharmaceuticals Inc.20-F - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Universe Pharmaceuticals Inc.SCHEDULE 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Universe Pharmaceuticals Inc.SCHEDULE 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)
- SECSEC Form 20-F filed by Universe Pharmaceuticals Inc.20-F - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- PRUniverse Pharmaceuticals INC Announces Share ConsolidationJiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company's issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the "Share Consolidation"). As a result of the Share Consolidation, each 40 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. Th
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- PRUniverse Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual ReportJi'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Com
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)
- SECSEC Form 6-K filed by Universe Pharmaceuticals Inc.6-K - Universe Pharmaceuticals INC (0001809616) (Filer)